Skip to main content
UniHealth

Doctor search

Jiali Li, MD

Hematology/Oncology · Los Gatos

NPI 1396981445

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
32
8 carriers
Office
1

Offices

1 location · El Camino Health Medical Network LLC · 202 clinicians in this group

Looking this up.

Hospitals listed: El Camino Health · Stanford Health Care. That is not proof they admit you there this week.

Plans that list them

32 plans · 8 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Li’s office at (408) 866-4070 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

32 of 32 plans

Plans whose provider directory lists this clinician
Alignment Health Advantage PPO (PPO)Alignment Health PlanListedOct 3, 2026
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Anthem Full Dual Advantage Aligned (HMO D-SNP)Anthem Blue CrossListedOct 3, 2026
Anthem Medicare Advantage (HMO-POS)Anthem Blue CrossListedOct 3, 2026
Anthem Prime (HMO-POS)Anthem Blue Cross Partnership PlanListedOct 3, 2026
Astiva Health C-SNP WOW - NorCal (HMO C-SNP)Astiva HealthListedSep 27, 2026
Astiva Health Premier Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Astiva Health Savings Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Blue Shield Inspire (HMO)Blue Shield of CaliforniaListedAug 26, 2026
Central Health Classic Care Plan III (HMO)Central Health Medicare PlanListedAug 15, 2026
Central Health Dual Access Plan (HMO D-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Embrace Care Plan (HMO C-SNP)Central Health Medicare PlanListed, may be out of dateSep 15, 2025
Central Health Embrace Choice Plan (HMO C-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Valor Care Plan (HMO)Central Health Medicare PlanListedAug 15, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026

California Medical Board record

Licence A105831 · Current

Licensed to practise in California · since 2008 · expires 2026-10-31 · Tianjin Medical College.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

2 hospitals

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend it
    Overall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
  • Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend it
    Overall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for El Camino Health

Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at El Camino Health
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.291BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.393BetterOct 2024 – Sep 2025
MRSA BacteremiaInfections0BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths0.96 (0.12 to 1.79) · 2,340 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.02 (0.76 to 1.28)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths167.38 (125.03 to 209.73) · 96 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.6 · 68 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.1 · 185 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths11.8 · 200 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths8.9 · 814 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths13 · 842 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths9.6 · 361 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.6 · 4,633 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.16 (0 to 0.34) · 11,474 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.27 (0.1 to 0.45) · 11,626 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.14 (1.39 to 4.9) · 2,814 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths2 (0.61 to 3.39) · 1,327 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.11 (0.8 to 3.43) · 2,641 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths9.39 (4.18 to 14.6) · 1,287 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths6.57 (3.47 to 9.68) · 1,308 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths2.14 (0.71 to 3.57) · 827 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.6 (0.05 to 1.15) · 9,460 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths4.5 · 122 casesNoneApr 2023 – Mar 2025
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.993No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.706No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.376No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits15.5 · 218 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits19.5 · 962 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits3.8 · 200 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-17 · 922 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits18.6 · 860 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits18.7 · 827 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits6.1 (4.5 to 8.2) · 313 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits13.4 (10.6 to 16.5) · 313 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits6.1 · 144 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits10.3 · 80 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits20.7 · 237 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.8 (10 to 16.1) · 1,639 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.9 (0.8 to 1.1) · 1,619 casesNo differentJan 2024 – Dec 2024

What patients said (1,535 patients answered, 22% of those asked)

Patient survey stars by topic at El Camino Health
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information3
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at El Camino Health
Room was "always" clean75%
Nurses "always" communicated well79%
Doctors "always" communicated well81%
Staff "always" explained61%
Yes, staff "did" give patients this information86%
Yes, staff "did" give patients information about help after discharge86%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)76%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand75%
Nurses "always" listened carefully76%
Nurses "always" treated them with courtesy and respect87%
"Always" quiet at night47%
"YES", patients would definitely recommend the hospital80%
Staff "always" explained possible side effects46%
Yes, staff "did" give patients information about possible symptoms86%
See every measure and the patient survey for Stanford Health Care

Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Stanford Health Care
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths5.31 (4.24 to 6.37) · 8,661 casesWorseJul 2022 – Jun 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits14.1 (12.7 to 15.7) · 2,191 casesWorseJan 2024 – Dec 2024
Postoperative respiratory failure rateComplications and deaths4.08 (1.95 to 6.21) · 5,296 casesBetterJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.317BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.446BetterOct 2024 – Sep 2025
SSI - Colon SurgeryInfections0.241BetterOct 2024 – Sep 2025
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits0.7 (0.6 to 0.9) · 3,348 casesBetterJan 2024 – Dec 2024
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.06 (0.45 to 1.67) · 5,374 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths0.86 (0.72 to 1)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths166.09 (137.88 to 194.3) · 470 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths1.1 · 192 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths6.4 · 146 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths9.7 · 253 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths6.3 · 880 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths10.3 · 935 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 501 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths2.1 · 7,730 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.13 (0 to 0.27) · 20,799 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.28 (0.14 to 0.43) · 23,182 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths0.94 (0.2 to 1.68) · 5,694 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths2.36 (1.54 to 3.19) · 7,846 casesNo differentJul 2022 – Jun 2024
Postoperative sepsis rateComplications and deaths5.2 (3.76 to 6.64) · 5,603 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.38 (0.23 to 2.53) · 2,211 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.52 (0.21 to 0.83) · 19,915 casesNo differentJul 2022 – Jun 2024
Rate of complications for hip/knee replacement patientsComplications and deaths3.6 · 416 casesNoneApr 2023 – Mar 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.869No differentOct 2024 – Sep 2025
MRSA BacteremiaInfections0.857No differentOct 2024 – Sep 2025
SSI - Abdominal HysterectomyInfections0.368No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16.2 · 247 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits20.5 · 1,021 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits47.8 · 258 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-1.6 · 990 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits20.8 · 976 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.5 · 959 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (4.4 to 6.2) · 2,191 casesNo differentJan 2024 – Dec 2024
Rate of readmission after hip/knee replacementUnplanned return visits5.1 · 425 casesNoneJul 2023 – Jun 2025
Rate of readmission for CABGUnplanned return visits9.6 · 158 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.6 · 183 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.7 (10.4 to 15.4) · 4,578 casesNo differentJan 2022 – Dec 2024

What patients said (6,810 patients answered, 25% of those asked)

Patient survey stars by topic at Stanford Health Care
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating4
Quietness2
Recommend hospital5
Share of patients giving the best answer at Stanford Health Care
Room was "always" clean75%
Nurses "always" communicated well82%
Doctors "always" communicated well81%
Staff "always" explained63%
Yes, staff "did" give patients this information89%
Yes, staff "did" give patients information about help after discharge89%
Doctors "always" explained things so they could understand76%
Doctors "always" listened carefully80%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)79%
Staff "always" explained new medications76%
Nurses "always" explained things so they could understand77%
Nurses "always" listened carefully79%
Nurses "always" treated them with courtesy and respect88%
"Always" quiet at night53%
"YES", patients would definitely recommend the hospital83%
Staff "always" explained possible side effects50%
Yes, staff "did" give patients information about possible symptoms90%

Original Medicare doctor bills

$395,760

Medicare paid this office $395,760 for 623 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Long return visit (40+ min)308$157,172$127
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes102$79,870$107
Return visit (30+ min)337$45,546$75
Long return visit (40+ min)82$26,659$175
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes113$22,742$115
See all 13 services
Every Original Medicare service billed
Long return visit (40+ min)308$157,172$127
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes102$79,870$107
Return visit (30+ min)337$45,546$75
Long return visit (40+ min)82$26,659$175
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes113$22,742$115
Return visit (30+ min)129$21,683$123
New patient visit (60+ min)102$16,105$158
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes47$10,887$70
Telephone medical discussion with physician, 21-30 minutes19$3,734$110
Initial hospital care with moderate level of medical decision making at least 75 minutes13$2,292$135
Telephone medical discussion with physician, 21-30 minutes21$2,099$87
Hospital discharge day management, more than 30 minutes12$1,711$107
New patient visit (45+ min)17$1,584$93

Who their Medicare patients are

623 Original Medicare patients in 2024. Average age 77 · Under 65 4% · 85 and older 19% · Women 58% · Also on Medicaid 14% · Health risk score 1.77. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 75% · Cancer 54% · Diabetes 34% · Coronary heart disease 31% · Chronic kidney disease 28% · Atrial fibrillation 21% · Heart failure 19% · COPD 16% · Depression 16% · Stroke 10% · Dementia 8%.

The office billed $1,851,064, Medicare allowed $519,738 and paid $395,760; for 3,539 services of 22 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20246233,539771.77$1,851,064$395,760
20235923,419771.68$1,719,382$367,913
20225723,740771.84$1,631,268$365,715
20215233,442771.80$1,430,003$349,938
20204482,884771.81$1,121,889$242,484
20194792,995772.05$1,162,387$255,464
20185023,303771.98$1,299,573$340,039
20174132,676771.93$1,023,747$289,082
20163672,038761.85$662,777$204,115
20152551,518761.84$472,936$154,680
20133482721.64$50,087$7,282

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 16 services

Original Medicare services billed in 2023
Long return visit (40+ min)229$133,366$127
Return visit (30+ min)367$66,667$83
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes85$64,105$109
Telephone medical discussion with physician, 21-30 minutes103$20,873$115
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes108$18,447$117
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes70$16,587$73
New patient visit (60+ min)86$13,400$156
Return visit (30+ min)67$12,735$117
Long return visit (40+ min)20$5,389$174
Initial hospital care with moderate level of medical decision making at least 75 minutes23$4,393$146
New patient visit (45+ min)20$2,402$120
Telephone medical discussion with physician, 21-30 minutes24$2,246$86
Hospital discharge day management, more than 30 minutes15$1,901$106
Short return visit (20+ min)12$1,065$89
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes12$811$45
Short return visit (20+ min)14$791$49

2022: 12 services

Original Medicare services billed in 2022
Return visit (30+ min)389$112,934$83
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes130$89,320$94
Telephone medical discussion with physician, 21-30 minutes244$60,945$115
Long return visit (40+ min)129$47,293$129
New patient visit (60+ min)85$13,128$154
Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes94$12,404$92
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes46$6,641$125
Initial hospital care with moderate level of medical decision making at least 75 minutes24$4,761$183
Short return visit (20+ min)41$3,716$55
Hospital discharge day management, more than 30 minutes19$2,270$99
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes20$1,970$68
Telephone medical discussion with physician, 21-30 minutes15$1,129$75

2021: 14 services

Original Medicare services billed in 2021
Return visit (30+ min)358$113,580$87
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes140$75,092$96
Long return visit (40+ min)150$55,157$129
Telephone medical discussion with physician, 21-30 minutes185$44,776$120
Initial hospital care with moderate level of medical decision making at least 75 minutes86$21,091$174
New patient visit (60+ min)71$11,868$167
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes54$9,381$125
Short return visit (20+ min)72$5,717$57
Hospital discharge day management, more than 30 minutes18$2,818$97
Subsequent hospital care with moderate levelof medical decision making at least 35 minutes17$1,903$68
Telephone medical discussion with physician, 11-20 minutes23$1,822$76
Telephone medical discussion with physician, 21-30 minutes15$1,405$88
Biopsy and aspiration of bone marrow sample for diagnosis12$951$73
Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes12$534$33

2020: 11 services

Original Medicare services billed in 2020
Return visit (30+ min)331$80,591$66
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes99$61,901$96
Long return visit (40+ min)123$39,845$99
Telephone medical discussion with physician, 21-30 minutes117$19,536$101
Initial hospital care with moderate level of medical decision making at least 75 minutes47$10,089$177
New patient visit (60+ min)64$9,203$144
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes36$6,946$114
Short return visit (20+ min)51$4,081$43
Hospital discharge day management, more than 30 minutes19$2,620$87
Telephone medical discussion with physician, 11-20 minutes27$2,237$70
Hospital discharge day management, 30 minutes or less11$1,164$68

2019: 11 services

Original Medicare services billed in 2019
Return visit (30+ min)361$97,364$70
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes131$64,687$95
Long return visit (40+ min)159$51,413$100
New patient visit (60+ min)67$10,203$152
Initial hospital care with moderate level of medical decision making at least 75 minutes44$8,329$181
Initial hospital care with straightforward or low-level medical decision making at least 55 minutes32$5,094$124
Return visit (30+ min)55$4,661$80
Follow-up observation care per day, typically 35 minutes18$3,544$93
Short return visit (20+ min)35$3,416$43
Long return visit (40+ min)13$1,727$133
Hospital discharge day management, 30 minutes or less11$814$68

2018: 7 services

Original Medicare services billed in 2018
Return visit (30+ min)399$168,549$97
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes134$77,424$94
Long return visit (40+ min)158$54,060$133
New patient visit (60+ min)79$14,834$188
Initial hospital care with moderate level of medical decision making at least 75 minutes63$11,408$181
Short return visit (20+ min)72$10,483$67
Hospital discharge day management, 30 minutes or less18$1,337$67

2017: 7 services

Original Medicare services billed in 2017
Return visit (30+ min)261$115,378$100
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes124$68,561$92
Long return visit (40+ min)167$65,225$134
New patient visit (60+ min)82$15,391$188
Initial hospital care with moderate level of medical decision making at least 75 minutes84$15,216$181
Short return visit (20+ min)43$4,664$67
Hospital discharge day management, 30 minutes or less15$1,938$65

2016: 7 services

Original Medicare services billed in 2016
Return visit (30+ min)226$106,777$95
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes106$49,768$90
New patient visit (60+ min)103$18,687$181
Initial hospital care with moderate level of medical decision making at least 75 minutes61$10,974$174
Long return visit (40+ min)55$9,370$130
Short return visit (20+ min)64$4,690$63
Hospital discharge day management, 30 minutes or less13$1,031$64

2015: 7 services

Original Medicare services billed in 2015
Return visit (30+ min)159$70,980$101
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes99$45,616$93
New patient visit (60+ min)72$13,404$186
Initial hospital care with moderate level of medical decision making at least 75 minutes54$9,763$181
Return visit (30+ min)49$4,112$65
Long return visit (40+ min)22$3,112$135
Short return visit (20+ min)33$3,022$69

2013: 2 services

Original Medicare services billed in 2013
Long return visit (40+ min)23$5,036$84
New patient visit (60+ min)18$2,195$122

Medicaid work

$789 in 2024

Medicaid paid $789 for 153 billed services this clinician did in 2024, up to 17 people in a month for one service.

Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.

Largest Medicaid services in 2024
Long return visit (40+ min)153$789
Medicaid work by year
2024153117$789
202392214$669
2022139124$1,131
2021112116$588
202075121$553
2019146219$705
2018314227$6,647
See the largest Medicaid services in earlier years

2023

Largest Medicaid services in 2023
Return visit (30+ min)15$338
Long return visit (40+ min)77$332

2022

Largest Medicaid services in 2022
Return visit (30+ min)139$1,131

2021

Largest Medicaid services in 2021
Return visit (30+ min)112$588

2020

Largest Medicaid services in 2020
Return visit (30+ min)75$553

2019

Largest Medicaid services in 2019
Return visit (30+ min)133$609
Long return visit (40+ min)13$96

2018

Largest Medicaid services in 2018
Return visit (30+ min)256$5,162
SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES58$1,485

Drugs they prescribed that Part D paid

$6,269,115

Pharmacies billed $6,269,115 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 5% of their Part D prescriptions (129 of 2,683) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%. Long-acting opioids: 19% of their opioid prescriptions.

1,962 generic and fewer than 11 brand-name prescriptions · $6,269,115 in drug cost · 44 antibiotic prescriptions to 29 people · 13 antipsychotic prescriptions to people over 65.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
Lenvima37$889,782$24,048
Tagrisso47$769,171$16,365
Cabometyx13$594,166$45,705
Verzenio40$574,191$14,355
Revlimid29$463,160$15,971
See all 63 drugs
Every Part D drug this clinician prescribed
Lenvima37$889,782$24,048
Tagrisso47$769,171$16,365
Cabometyx13$594,166$45,705
Verzenio40$574,191$14,355
Revlimid29$463,160$15,971
Imbruvica31$459,226$14,814
Lynparza30$434,569$14,486
Ibrance28$390,418$13,943
Brukinsa15$226,117$15,074
Lenalidomide20$216,971$10,849
Xtandi12$176,595$14,716
Eliquis151$119,595$792
Stivarga11$61,786$5,617
Imatinib Mesylate38$56,558$1,488
Orgovyx14$37,682$2,692
Xarelto20$21,337$1,067
Abiraterone Acetate13$20,165$1,551
Creon21$18,591$885
Exemestane95$18,353$193
Linzess12$9,563$797
Megestrol Acetate45$2,179$48
Levothyroxine85$2,170$26
Anastrozole126$2,009$16
Hydrocodone-Acetaminophen53$1,544$29
Hydroxyurea58$1,192$21
Ursodiol16$1,192$74
Letrozole67$1,031$15
Ondansetron42$999$24
Pantoprazole82$946$12
Hydrocortisone39$848$22
Bicalutamide22$738$34
Tamoxifen Citrate38$682$18
Nystatin26$587$23
Potassium Chloride48$562$12
Erlotinib12$532$44
Venlafaxine Hcl Er18$529$29
Prednisone84$525$6
Morphine Sulfate Er18$520$29
Gabapentin43$485$11
Diphenoxylate-Atropine19$482$25
Lorazepam65$430$7
Dexamethasone17$341$20
Morphine Sulfate13$328$25
Tenofovir Disoproxil11$287$26
Acyclovir24$282$12
Furosemide77$274$4
Zolpidem55$270$5
Warfarin18$217$12
Trazodone77$211$3
Metoprolol15$209$14
Oxycodone17$208$12
Losartan19$207$11
Omeprazole17$194$11
Alprazolam20$131$7
Hydroxyzine11$130$12
Metoclopramide32$128$4
Amlodipine Besylate29$118$4
Folic Acid12$110$9
Metformin11$66$6
Lisinopril14$43$3
Azithromycin14$33$2
Alendronate18$31$2
Ibuprofen11$22$2

Year by year

Part D prescribing by year
20242,6833585% (129)None$6,269,115
20231,5962736% (91)None$2,683,890
20221,0902104% (46)None$1,704,448
20211,1362016% (72)None$1,769,621
20201,2831866% (72)None$1,713,312
20191,4962295% (69)None$2,410,114
20182,1002475% (108)26%$3,626,944
20171,4231724% (60)None$1,749,281
20169831307% (66)None$1,341,744
2015717928% (57)28%$594,084
2014339659% (29)22%$177,761
2013227475% (11)12%$24,484

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 45 drugs

Part D drugs prescribed in 2023
Lenvima25$599,257$23,970
Lenalidomide19$243,661$12,824
Revlimid14$240,263$17,162
Xtandi11$119,618$10,874
Abiraterone Acetate11$90,483$8,226
Eliquis59$46,263$784
Linzess21$12,866$613
Exemestane35$6,464$185
Tenofovir Disoproxil12$2,244$187
Megestrol Acetate27$2,088$77
Hydroxyurea43$1,374$32
Anastrozole34$1,214$36
Pantoprazole54$1,036$19
Levothyroxine45$928$21
Ursodiol19$869$46
Letrozole32$830$26
Potassium Chloride38$725$19
Hydrocodone-Acetaminophen24$668$28
Ondansetron21$655$31
Lorazepam54$567$10
Tamoxifen Citrate16$529$33
Prednisone72$495$7
Morphine Sulfate Er16$493$31
Diphenoxylate-Atropine19$464$24
Sodium Chloride23$453$20
Losartan16$443$28
Bicalutamide13$357$27
Albuterol Sulfate Hfa14$356$25
Amlodipine Besylate19$349$18
Oxycodone22$346$16
Dexamethasone25$337$13
Acyclovir18$299$17
Gabapentin25$288$12
Trazodone33$283$9
Zolpidem42$265$6
Hydrocortisone15$264$18
Furosemide38$208$5
Venlafaxine Hcl Er22$162$7
Metoclopramide12$161$13
Ciprofloxacin12$108$9
Lisinopril13$102$8
Alprazolam14$93$7
Metformin11$77$7
Azithromycin12$62$5
Metoprolol11$61$6

2022: 29 drugs

Part D drugs prescribed in 2022
Revlimid50$912,745$18,255
Eliquis30$18,258$609
Xarelto21$12,931$616
Ursodiol13$3,257$251
Exemestane17$2,455$144
Megestrol Acetate27$1,638$61
Ondansetron21$853$41
Potassium Chloride27$694$26
Pantoprazole53$575$11
Hydrocodone-Acetaminophen18$494$27
Tamoxifen Citrate16$444$28
Gabapentin35$439$13
Hydroxyurea11$435$40
Prednisone65$407$6
Bicalutamide12$357$30
Dexamethasone18$348$19
Diphenoxylate-Atropine11$347$32
Lorazepam47$278$6
Letrozole20$269$13
Oxycodone-Acetaminophen11$252$23
Zolpidem22$198$9
Dicyclomine12$190$16
Levothyroxine16$170$11
Metoclopramide18$145$8
Hydrocortisone13$131$10
Trazodone22$118$5
Furosemide27$104$4
Atorvastatin16$103$6
Lisinopril11$27$2

2021: 31 drugs

Part D drugs prescribed in 2021
Revlimid49$839,950$17,142
Tagrisso16$264,001$16,500
Ibrance12$155,692$12,974
Eliquis26$16,724$643
Creon13$14,248$1,096
Exemestane16$2,351$147
Lidocaine14$2,175$155
Potassium Chloride31$1,488$48
Hydroxyurea14$1,172$84
Letrozole22$942$43
Dexamethasone41$923$23
Hydrocodone-Acetaminophen33$839$25
Megestrol Acetate19$777$41
Ondansetron15$681$45
Pantoprazole46$621$14
Tamoxifen Citrate19$609$32
Levothyroxine31$573$18
Hydrocortisone24$557$23
Lorazepam55$359$7
Prednisone45$293$7
Diphenoxylate-Atropine11$247$22
Furosemide38$208$5
Anastrozole14$192$14
Alprazolam12$157$13
Allopurinol11$135$12
Gabapentin15$91$6
Metoclopramide17$88$5
Zolpidem16$82$5
Trazodone15$73$5
Metoprolol11$56$5
Amlodipine Besylate12$46$4

2020: 35 drugs

Part D drugs prescribed in 2020
Revlimid26$517,350$19,898
Tagrisso24$383,730$15,989
Ibrance18$228,281$12,682
Erlotinib13$68,761$5,289
Eliquis38$18,029$474
Exemestane50$15,266$305
Lidocaine12$2,346$195
Tamoxifen Citrate23$1,607$70
Clindamycin Phosphate13$1,353$104
Bicalutamide22$1,349$61
Megestrol Acetate24$1,076$45
Hydroxyurea25$928$37
Pregabalin12$716$60
Nystatin30$699$23
Hydrocortisone26$679$26
Potassium Chloride42$666$16
Minocycline15$637$42
Ondansetron23$548$24
Dexamethasone29$539$19
Hydrocodone-Acetaminophen22$526$24
Lorazepam56$471$8
Pantoprazole25$471$19
Lidocaine Hcl Viscous14$455$33
Letrozole17$449$26
Anastrozole25$449$18
Triamcinolone Acetonide11$432$39
Prednisone57$374$7
Levothyroxine15$285$19
Furosemide48$212$4
Levofloxacin11$194$18
Gabapentin16$185$12
Zolpidem30$143$5
Metoclopramide15$93$6
Amlodipine Besylate23$82$4
Ciprofloxacin11$48$4

2019: 40 drugs

Part D drugs prescribed in 2019
Revlimid39$726,525$18,629
Tagrisso29$450,022$15,518
Ibrance16$181,358$11,335
Imbruvica12$138,676$11,556
Imatinib Mesylate23$119,647$5,202
Xtandi12$97,985$8,165
Exemestane83$21,311$257
Eliquis30$14,523$484
Xarelto16$11,146$697
Lidocaine20$3,141$157
Tamoxifen Citrate53$1,518$29
Megestrol Acetate22$1,378$63
Amoxicillin-Clavulanate Potass17$1,325$78
Minocycline12$1,129$94
Potassium Chloride41$1,089$27
Pantoprazole55$1,052$19
Anastrozole58$1,012$17
Droxia23$951$41
Hydroxyurea23$764$33
Bicalutamide28$675$24
Dexamethasone18$538$30
Levothyroxine32$526$16
Hydrocodone-Acetaminophen22$522$24
Lorazepam61$503$8
Nystatin16$386$24
Prednisone46$313$7
Ondansetron18$287$16
Letrozole15$256$17
Zolpidem20$256$13
Hydrocortisone19$216$11
Gabapentin18$214$12
Alprazolam22$213$10
Furosemide44$200$5
Atorvastatin20$178$9
Amlodipine Besylate23$162$7
Tamsulosin14$158$11
Omeprazole13$119$9
Oxycodone13$113$9
Losartan21$109$5
Ciprofloxacin14$86$6

2018: 49 drugs

Part D drugs prescribed in 2018
Revlimid69$973,441$14,108
Tagrisso31$470,892$15,190
Ibrance39$457,474$11,730
Afinitor18$298,008$16,556
Imbruvica20$258,961$12,948
Tarceva29$238,484$8,224
Xtandi19$162,953$8,576
Tafinlar11$103,804$9,437
Imatinib Mesylate11$84,198$7,654
Exemestane114$39,859$350
Xarelto45$23,610$525
Eliquis39$18,450$473
Lidocaine27$6,125$227
Anagrelide12$3,898$325
Potassium Chloride60$3,004$50
Anastrozole100$1,779$18
Tamoxifen Citrate41$1,648$40
Hydroxyurea46$1,271$28
Ondansetron54$1,143$21
Megestrol Acetate30$924$31
Diphenoxylate-Atropine12$807$67
Oxycodone-Acetaminophen13$795$61
Nystatin29$683$24
Pantoprazole66$656$10
Dexamethasone39$601$15
Hydrocodone-Acetaminophen25$580$23
Zolpidem54$498$9
Letrozole51$489$10
Oxycodone27$414$15
Valsartan11$378$34
Lorazepam85$367$4
Amoxicillin-Clavulanate Potass12$359$30
Hydrocortisone26$343$13
Levothyroxine33$316$10
Gabapentin36$274$8
Tamsulosin27$271$10
Prednisone40$248$6
Diazepam12$220$18
Minocycline11$196$18
Metoclopramide36$194$5
Levofloxacin15$175$12
Venlafaxine Hcl Er15$166$11
Alprazolam19$139$7
Tramadol19$121$6
Ibuprofen13$121$9
Amlodipine Besylate31$120$4
Furosemide41$98$2
Azithromycin15$88$6
Simvastatin16$52$3

2017: 37 drugs

Part D drugs prescribed in 2017
Revlimid47$657,911$13,998
Tarceva50$361,672$7,233
Imbruvica15$177,153$11,810
Xarelto63$27,701$440
Exemestane45$21,034$467
Entecavir13$11,798$908
Eliquis19$8,928$470
Potassium Chloride48$1,558$32
Anagrelide14$1,215$87
Ondansetron41$1,158$28
Pantoprazole91$1,146$13
Clindamycin Phosphate13$1,065$82
Anastrozole65$1,045$16
Diphenoxylate-Atropine20$920$46
Hydroxyurea45$909$20
Nystatin24$863$36
Levofloxacin17$734$43
Oxycodone25$565$23
Minocycline18$492$27
Triamcinolone Acetonide18$384$21
Dexamethasone25$365$15
Hydrocortisone19$351$18
Levothyroxine16$348$22
Gabapentin23$309$13
Letrozole35$301$9
Loperamide12$292$24
Lorazepam54$291$5
Ondansetron Odt12$290$24
Prednisone32$227$7
Tamsulosin14$225$16
Zolpidem25$192$8
Venlafaxine Hcl Er18$144$8
Furosemide23$107$5
Metoclopramide27$100$4
Amlodipine Besylate13$94$7
Azithromycin13$75$6
Simvastatin18$35$2

2016: 27 drugs

Part D drugs prescribed in 2016
Revlimid33$399,666$12,111
Tarceva52$341,185$6,561
Imbruvica19$197,884$10,415
Nexavar11$96,131$8,739
Xarelto35$13,753$393
Eliquis26$10,440$402
Exemestane34$9,036$266
Ondansetron30$1,035$34
Anagrelide13$975$75
Hydrocodone-Acetaminophen34$956$28
Warfarin21$756$36
Dexamethasone46$699$15
Voltaren14$692$49
Anastrozole42$647$15
Hydroxyurea35$568$16
Potassium Chloride18$406$23
Pantoprazole27$357$13
Oxycodone17$322$19
Lorazepam44$265$6
Levofloxacin19$208$11
Gabapentin22$197$9
Hydrocortisone13$169$13
Acyclovir11$113$10
Prednisone15$91$6
Metoclopramide18$70$4
Furosemide11$26$2
Hydrochlorothiazide11$21$2

2015: 27 drugs

Part D drugs prescribed in 2015
Tarceva34$181,139$5,328
Imbruvica15$150,715$10,048
Xarelto35$13,258$379
Exemestane21$5,492$262
Tradjenta12$3,994$333
Advair Diskus12$3,703$309
Repaglinide13$1,401$108
Dronabinol12$1,064$89
Fentanyl11$700$64
Hydroxyurea21$675$32
Ondansetron25$529$21
Dexamethasone26$425$16
Oxycodone17$418$25
Zolpidem13$342$26
Anastrozole28$341$12
Levothyroxine15$323$22
Lorazepam44$220$5
Hydrocodone-Acetaminophen13$217$17
Levofloxacin15$153$10
Prednisone22$128$6
Gabapentin20$123$6
Acyclovir13$102$8
Potassium Chloride11$98$9
Furosemide22$85$4
Amlodipine Besylate13$79$6
Hydrochlorothiazide14$42$3
Simvastatin11$20$2

2014: 6 drugs

Part D drugs prescribed in 2014
Xarelto18$5,957$331
Anastrozole39$1,238$32
Ondansetron22$317$14
Dexamethasone12$167$14
Prednisone22$142$6
Azithromycin13$114$9

2013: 3 drugs

Part D drugs prescribed in 2013
Exemestane34$8,096$238
Anastrozole52$2,207$42
Letrozole23$492$21

Money from drug and device companies

$74 in 2025

Industry payments by year
202522None$74
202322None$38
202233None$74
202111None$12
20201315None$317
20191970None$1,352

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
AstraZeneca Pharmaceuticals LPEnhertu$43
1 payment
  • Education for Enhertu · 2025-11-19 · $43
PfizerIbrance$31
1 payment
  • Education for Ibrance · 2025-07-10 · $31
See all 2 published payments
Every published payment
AstraZeneca Pharmaceuticals LPEducation · 2025-11-19Enhertu$43
PfizerEducation · 2025-07-10Ibrance$31
See earlier years (2023, 2022, 2021, 2020, 2019)

2023: $38

Payments by company in 2023
PfizerIbrance$25
1 payment
  • Education for Ibrance · 2023-07-27 · $25
Janssen PharmaceuticalsNone$13
1 payment
  • Education · 2023-08-17 · $13

2022: $74

Payments by company in 2022
SeagenPadcev$41
1 payment
  • Meals for Padcev · 2022-01-31 · $41
Novartis PharmaceuticalsNone$22
1 payment
  • Meals · 2022-10-27 · $22
Merck Sharp & DohmeKeytruda$11
1 payment
  • Education for Keytruda · 2022-11-02 · $11

2021: $12

Payments by company in 2021
Gilead SciencesNone$12
1 payment
  • Education · 2021-06-01 · $12

2020: $317

Payments by company in 2020
SeagenAdcetris$54
2 payments
  • Meals for Adcetris · 2020-03-04 · $30
  • Meals for Padcev · 2020-01-29 · $25
AstraZeneca Pharmaceuticals LPLynparza$36
2 payments
  • Meals for Lynparza · 2020-03-12 · $21
  • Meals for Imfinzi · 2020-01-15 · $15
EisaiLenvima$27
1 payment
  • Meals for Lenvima · 2020-02-26 · $27
Blueprint MedicinesAyvakit$25
1 payment
  • Meals for Ayvakit · 2020-03-16 · $25
PfizerXtandi$24
1 payment
  • Meals for Xtandi · 2020-02-24 · $24
Lilly USAAlimta$22
1 payment
  • Meals for Alimta · 2020-02-10 · $22
Bayer HealthCare PharmaceuticalsNubeqa$22
1 payment
  • Meals for Nubeqa · 2020-02-12 · $22
Merck Sharp & DohmeKeytruda$20
1 payment
  • Meals for Keytruda · 2020-02-19 · $20
Novartis PharmaceuticalsTasigna$20
1 payment
  • Meals for Tasigna · 2020-01-27 · $20
Janssen BiotechDarzalex$18
1 payment
  • Meals for Darzalex · 2020-02-05 · $18
Puma BiotechnologyNerlynx$17
1 payment
  • Meals for Nerlynx · 2020-02-03 · $17
CelgeneRevlimid$17
1 payment
  • Meals for Revlimid · 2020-01-09 · $17
Foundation MedicineFoundationone$16
1 payment
  • Meals for Foundationone · 2020-01-28 · $16

2019: $1,352

Payments by company in 2019
Novartis PharmaceuticalsVotrient$157
8 payments
  • Meals for Votrient · 2019-09-09 · $22
  • Meals for Tasigna · 2019-07-31 · $17
  • Meals for Piqray · 2019-07-22 · $24
  • Meals for Tasigna · 2019-06-17 · $17
  • Meals for Votrient · 2019-06-03 · $20
  • Meals for Promacta · 2019-04-10 · $18
  • Meals for Promacta · 2019-02-20 · $23
  • Meals for Mekinist · 2019-02-04 · $18
Lilly USAAlimta$155
8 payments
  • Meals for Erbitux · 2019-10-23 · $23
  • Meals for Alimta · 2019-09-19 · $20
  • Meals for Verzenio · 2019-08-28 · $15
  • Meals for Alimta · 2019-07-10 · $20
  • Meals for Alimta · 2019-06-12 · $19
  • Meals for Erbitux · 2019-05-15 · $13
  • Meals for Alimta · 2019-04-17 · $22
  • Meals for Alimta · 2019-02-27 · $24
E.R. Squibb & Sons L.L.C.Opdivo$151
8 payments
  • Meals for Opdivo · 2019-11-06 · $24
  • Meals for Opdivo · 2019-09-30 · $17
  • Meals for Opdivo · 2019-08-21 · $20
  • Meals for Empliciti · 2019-06-26 · $16
  • Meals for Opdivo · 2019-05-13 · $21
  • Meals · 2019-04-03 · $15
  • Meals for Empliciti · 2019-03-27 · $22
  • Meals for Empliciti · 2019-01-16 · $18
Takeda Pharmaceuticals U.S.A.None$138
5 payments
  • Meals · 2019-12-09 · $30
  • Meals · 2019-09-04 · $26
  • Meals · 2019-05-01 · $28
  • Meals · 2019-03-04 · $31
  • Meals · 2019-01-30 · $24
Merck Sharp & DohmeKeytruda$125
7 payments
  • Meals for Keytruda · 2019-12-18 · $20
  • Meals for Keytruda · 2019-11-20 · $14
  • Meals for Keytruda · 2019-07-15 · $19
  • Meals for Keytruda · 2019-07-01 · $15
  • Meals for Lynparza · 2019-05-15 · $17
  • Meals for Keytruda · 2019-03-18 · $19
  • Meals for Keytruda · 2019-02-06 · $20
PfizerIbrance$81
5 payments
  • Meals for Ibrance · 2019-12-08 · $11
  • Meals for Xalkori · 2019-11-04 · $20
  • Meals for Xtandi · 2019-10-16 · $24
  • Meals for Ibrance · 2019-03-07 · $12
  • Meals for Ibrance · 2019-02-11 · $14
Bayer HealthCare PharmaceuticalsXofigo$74
4 payments
  • Meals for Nubeqa · 2019-12-11 · $18
  • Meals for Nubeqa · 2019-08-12 · $17
  • Meals for Xofigo · 2019-03-20 · $17
  • Meals for Xofigo · 2019-01-10 · $22
AstraZeneca Pharmaceuticals LPImfinzi$72
4 payments
  • Meals for Imfinzi · 2019-10-09 · $17
  • Meals for Lynparza · 2019-08-19 · $21
  • Meals for Imfinzi · 2019-06-19 · $17
  • Meals for Faslodex · 2019-01-28 · $17
AmgenNplate$53
2 payments
  • Meals for Kanjinti · 2019-10-23 · $23
  • Meals for Nplate · 2019-02-25 · $29
IncyteJakafi$52
3 payments
  • Meals for Jakafi · 2019-11-18 · $16
  • Meals for Jakafi · 2019-08-16 · $14
  • Meals for Jakafi · 2019-03-12 · $22
Rigel PharmaceuticalsTavalisse$51
2 payments
  • Meals for Tavalisse · 2019-08-07 · $25
  • Meals for Tavalisse · 2019-05-29 · $26
CelgeneRevlimid$49
3 payments
  • Meals for Revlimid · 2019-12-05 · $18
  • Meals for Revlimid · 2019-09-12 · $15
  • Meals for Revlimid · 2019-04-02 · $16
EMD SeronoBavencio$46
3 payments
  • Meals for Bavencio · 2019-07-17 · $18
  • Meals for Bavencio · 2019-06-05 · $14
  • Meals for Bavencio · 2019-05-22 · $13
TesaroZejula$42
2 payments
  • Meals for Zejula · 2019-04-24 · $23
  • Meals for Zejula · 2019-01-23 · $19
Seattle GeneticsAdcetris$42
2 payments
  • Meals · 2019-10-07 · $30
  • Education for Adcetris · 2019-03-13 · $12
Janssen BiotechDarzalex$24
1 payment
  • Meals for Darzalex · 2019-03-13 · $24
EisaiHalaven$16
1 payment
  • Meals for Halaven · 2019-06-10 · $16
Foundation MedicineFoundationone$13
1 payment
  • Meals for Foundationone · 2019-08-05 · $13
Clovis OncologyRubraca$12
1 payment
  • Meals for Rubraca · 2019-12-02 · $12

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2 Breast Cancer Keynote-756 · 2021Their institution$62,972
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2- Breast Cancer Keynote-756 · 2019Their institution$53,306
Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2- Breast Cancer Keynote-756 · 2020Their institution$21,186
Merck Sharp & Dohme LLC · A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Er,Her2 Breast Cancer Keynote-756 · 2022Their institution$14,038

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score
83.6 / 100
Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI
1396981445
Licence
CA A105831California A105831: Current · expires 2026-10-31
Video visits
Lists video visits
Gender
Female
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207RH0003X (207RH0003X)
Mailing address
2505 Hospital Dr, Mountain View, CA, 94040
NPI first listed
2008-12-19
NPI last updated
2020-11-30
NPI record certified
2020-11-30

This is when the NPI record was last certified, not a medical board exam.